Look­ing to carve away mar­ket share from Gilead, Vi­iV and J&J score pos­i­tive PhI­II da­ta for a month­ly, 2-drug HIV in­jectable

Vi­iV Health­care’s fu­ture de­pends on its abil­i­ty to carve away mar­ket share from the block­buster com­bi­na­tion drugs that Gilead us­es to dom­i­nate the HIV mar­ket. And they took an­oth­er step to­ward that fu­ture to­day with a set of head­line re­sults point­ing to the suc­cess of a once-month­ly in­jectable in keep­ing the virus at bay in a big Phase III study — match­ing up nice­ly with a stan­dard dai­ly three-drug oral com­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER